Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03805698 · ClinicalTrials.gov registry record · NA
Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears
A NA study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03805698 is a NA study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT03805698, a NA study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The objective of this study is to compare outcomes and functionality measures of subjects treated with platelet rich plasma (PRP) after arthroscopic debridement of triangular fibrocartilage complex (TFCC) tears to subjects treated with arthroscopic debridement alone.
Interventions
- DEVICE Platelet-rich Plasma (PRP)
- OTHER Standard Arthroscopic Debridement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-01-03 |
| Est. Completion | 2021-02-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03805698
The ClinicalTrials.gov registry entry for NCT03805698 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Platelet-rich Plasma (PRP) is the first listed.
NCT03805698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03805698 about?
NCT03805698 is a clinical study titled "Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears". The objective of this study is to compare outcomes and functionality measures of subjects treated with platelet rich plasma (PRP) after arthroscopic debridement of triangular fibrocartilage complex (TFCC) tears to subjects treated with arthroscopic debridement alone.
What is the current status of trial NCT03805698?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2019-01-03. Estimated completion is 2021-02-06.
What interventions are being tested in trial NCT03805698?
The interventions under investigation include: Platelet-rich Plasma (PRP) (DEVICE), Standard Arthroscopic Debridement (OTHER).
Who is sponsoring clinical trial NCT03805698?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.